Results 121 to 130 of about 65,156 (262)

Oral Immunotherapy Induces Shift in lncRNA Expression Modulating Allergen‐Specific Immune Responses

open access: yesAllergy, EarlyView.
We used PBMC transcriptome from 50 hen's egg‐allergic patients to study the role of lncRNA in OIT. Positive correlation was found between 17 lncRNAs and the IL‐4/IL‐13 pathway in vivo, and the expression of the selected lncRNA aligned with CXCL8 upon PBMC egg‐restimulation.
Olivia Liong   +5 more
wiley   +1 more source

IgE, anti-IgE therapy, and regulatory T cells: new paradigms in allergic inflammation. [PDF]

open access: yesFront Allergy
Benito-Villalvilla C   +4 more
europepmc   +1 more source

Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human‐Mouse KIT

open access: yes
Allergy, EarlyView.
Hye‐Sook Kwon   +14 more
wiley   +1 more source

Basophil Activation Test as Biomarker of Severity and Threshold of Allergic Reactions to Cow's Milk During Oral Food Challenges

open access: yesAllergy, EarlyView.
The threshold of reactivity during fresh milk challenges was 70% lower than that of baked milk challenges, reflecting the higher allergenicity of fresh milk. BAT was the only biomarker statistically significantly different between severity and threshold groups, for baked milk and fresh milk allergies, respectively.
Holly Boyd   +17 more
wiley   +1 more source

Proteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U‐BIOPRED Cohort

open access: yesAllergy, EarlyView.
No stable features were identified as associated with asthma symptom control in transcriptomics or sputum proteomics. Higher TWEAKR/TNFRSF12A and MBL/MBP‐C serum levels increased the odds of uncontrolled symptoms, while higher MK08/MAPK8 and CD5L serum levels decreased the odds, after adjustment for clinical variables.
Joana Antão   +294 more
wiley   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy